Rising Biosciences, Inc. engages in the research and development of alternative patient care treatments. The company is headquartered in Tustin, California. The company went IPO on 2001-06-21. The firm is focused on oral and topical cannabis and non-cannabis-based pharmaceuticals. The firm operates through three distinct business units. In addition to Oxi Thyme, the second business unit is a physician’s practice management company focused on the proper use of cannabis for the treatment of chronic pain, opioid addiction, and terminal patients. The third business unit is a research and development company focused on oral and topical pharmaceuticals. Through its subsidiaries and investment holdings, the Company is focused on the treatment of individuals in both inpatient and outpatient environments recovering from alcohol and drug addiction.
根據最新的財務報表(Form-10K),PT Bank Negara Indonesia (Persero) Tbk 的總資產為 $0,淨損失為 $0
RBII 的關鍵財務比率是什麼?
PT Bank Negara Indonesia (Persero) Tbk 的流動比率為 0,淨利潤率為 0,每股銷售為 $0。
Rising Biosciences Inc 的收入按細分市場或地理位置如何劃分?
PT Bank Negara Indonesia (Persero) Tbk 最大收入來源為 Consumer Banking,在最近的收益報告中收入為 21,914,186,000,000。就地區而言,Indonesia 是 PT Bank Negara Indonesia (Persero) Tbk 的主要市場,收入為 62,879,130,000,000。
Rising Biosciences Inc 是否盈利?
無,根據最新的財務報表,PT Bank Negara Indonesia (Persero) Tbk 的淨損失為 $0